Cargando...
Systemic steroid treatment can desensitize the skin reaction due to regorafenib in a recurrence colorectal cancer patient
Oral intake of regorafenib has been shown to have survival benefits in patients with metastatic colorectal cancer progressing on standard therapies. However, because of adverse effects, the patients sometimes cannot continue treatment with regorafenib. Currently, there is no established supportive t...
Gardado en:
| Publicado en: | Int Cancer Conf J |
|---|---|
| Main Authors: | , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Springer Singapore
2019
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6744540/ https://ncbi.nlm.nih.gov/pubmed/31559116 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13691-019-00376-4 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|